The aim of the Fund is to achieve capital growth.
Name | % Net Assets |
---|---|
Pfizer Inc. | 8.7% |
Johnson & Johnson | 8.6% |
Novartis AG | 7.1% |
Roche Holding AG | 7.0% |
Merck & Co. Inc. | 5.3% |
Abbott Laboratories | 5.1% |
GlaxoSmithKline PLC | 3.8% |
Amgen Inc. | 3.2% |
Bristol-Myers Squibb Co. | 3.2% |
Essilor International S.A. | 3.1% |
Key | % Net Assets |
---|---|
Pfizer Inc. | 8.7% |
Johnson & Johnson | 8.6% |
Novartis AG | 7.1% |
Roche Holding AG | 7.0% |
Other | 68.6% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 15/07/2002 |
---|---|
Fund Manager | Stephen Thornber |
TER | - |
Minimum Investment | |
---|---|
Initial | 500000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | -0.08 |
You are here: research